Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Journal of Clinical & Experimental OncologyISSN: 2324-9110
Borje S Andersson Author
Subjects of specialization
Affiliation
Mucoepidermoid carcinoma, Cancer chemotherapy, Prostate biomarker
Department of Stem Cell Transplantation & Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Biography
Borje S Andersson was working in the Department of Stem Cell Transplantation & Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Doctor has more than 40 publications. Doctor's current research area related to clinical oncology.
Publications
Research Article Open Access
Synergism of the Anthracene-Derivative Anti-Cancer Agent Bisantrene with Nucleoside Analogs and A Bcl-2 Inhibitor in Acute Myeloid Leukemia Cells
Author(s): Benigno C Valdez, David Murray, Yang Li, Yan Liu, Yago Nieto, Uday Popat and Borje S Andersson
Bisantrene is an anthracene derivative with anti-tumor activity. Unlike the anthracyclines, it has virtually no clinical cardiotoxicity. We hypothesized that its combination with nucleoside analogs and the BCL-2 inhibitor ABT199 would provide improved cytotoxicity in AML cell cultures. Cells were exposed to drugs for 48 hrs and analyzed by MTT assay for cell proliferation, annexin V assay for apoptosis, Western blotting for changes in the status of protein levels and modifications, and flow cytometry for changes in Reactive Oxygen Species (ROS) and Mitochondrial Membrane Potential (MMP). Exposure of OCI-AML3 and MOLM14 cells to bisantrene+nucleoside analog(s) (cytarabine, cladribine, fludarabine/Flu or clofarabine/Clo)+ABT199 resulted in increased cytotoxicity, apoptosis and synergism w... view more»
Google Scholars / Researchers Sites
